Skip to content

#FDA

Today 0 items
Oct 5Mon
  1. nature.com75

    COPD trial wins spur broad respiratory hopes

    AstraZeneca's tozorakimab, an IL-33-targeted antibody, reduced COPD exacerbations by up to 30% in current and former smokers in two trials, with an FDA decision expected in the first quarter of 2027. Unlike dupilumab and mepolizumab, it worked across patients with all blood eosinophil counts, addressing non-eosinophilic COPD. The success, after mixed results for other IL-33 agents like itepekimab, is reviving industry interest in IL-33 and alarmin targets across respiratory disease.

    Why it matters: First IL-33 win in COPD works regardless of eosinophil count, reshaping the inflammatory biologic landscape.

Aug 31Mon
  1. Lancet73

    Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

    Switching virologically suppressed adults with HIV-1 to a once-weekly, single-tablet regimen of islatravir (2 mg)-lenacapavir (300 mg) was non-inferior to continuing daily oral standard of care in the phase 3 ISLEND-2 trial. At week 48, HIV-1 RNA viral load of 50 copies per mL or higher occurred in 1 of 314 participants on islatravir-lenacapavir versus 4 of 312 on standard of care, meeting the non-inferiority margin of 4%. Treatment-related adverse events occurred in 18% of the islatravir-lenacapavir group versus fewer than 1% of the standard-of-care group, though discontinuations due to adverse events were rare in both groups.

    Why it matters: Phase 3 data support the first once-weekly complete oral single-tablet regimen for HIV-1 treatment.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org